| Version |
2.5 |
| Creation Date |
2005-06-13 13:24:05 |
| Update Date |
2009-02-19 16:03:55 |
| Primary Accession Number |
DB00254 |
| Secondary Accession Number |
|
| Name |
Doxycycline |
| Drug Type |
- Approved
- Investigational
- Small Molecule
|
| Description |
A synthetic tetracycline derivative with similar antimicrobial activity. Animal studies suggest that it may cause less tooth staining than other tetracyclines. It is used in some areas for the treatment of chloroquine-resistant falciparum malaria (malaria, falciparum). [PubChem] |
| Synonyms |
- Doxcycline anhydrous
- Doxycycline Hyclate
- Doxycycline Monohydrate
- Doxytetracycline
|
| Brand Names |
- Alti-Doxycycline
- Apo-Doxy
- Atridox
- Doryx
- Doxy 100
- Doxy-Caps
- Doxy-Lemmon
- Doxychel
- Doxychel Hyclate
- Doxycin
- Doxylin
- Doxytec
- Jenacyclin
- Monodox
- Novo-Doxylin
- Nu-Doxycycline
- Oracea
- Periostat
- Supracyclin
- Vibra-Tabs
- Vibramycin
|
| Brand Mixtures |
Not Available |
| Chemical IUPAC Name |
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-(amino-hydroxymethylidene)-4-dimethylamino-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione |
| Chemical Formula |
C22H24N2O8 |
| Chemical Structure |
 |
| CAS Registry Number |
564-25-0 |
| InChI Identifier |
InChI=1/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,31-32H,23H2,1-3H3/b21-13-/t7-,10+,14+,15-,17-,22-/m0/s1 |
| InChI Key |
UEVKMCOZLJYVNG-NMMSOKQRBG |
| KEGG Drug |
Not Available |
| KEGG Compound |
C06973  |
| PubChem Compound |
5281011  |
| PubChem Substance |
154560  |
| ChEBI ID |
Not Available |
| PharmGKB ID |
PA449415  |
| HET ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
00742562  |
| RxList Link |
http://www.rxlist.com/cgi/generic/doxycyc.htm  |
| PDRhealth Link |
Not Available |
| Wikipedia Link |
http://en.wikipedia.org/wiki/Doxycycline  |
| FDA Label |
|
| Material Safety Data Sheet (MSDS) |
|
| Synthesis Reference |
C. R. Stephens et al.; J. Am. Chem. Soc. 80; 5324 (1958) |
| Average Molecular Weight |
444.4346 |
| Monoisotopic Molecular Weight |
444.1533 |
| State |
Solid |
| Melting Point |
201 oC |
| Experimental Water Solubility |
630 mg/L
Source: PhysProp
|
| Predicted Water Solubility |
5.16e-01 mg/mL
Calculated using ALOGPS
|
| Experimental LogP/Hydrophobicity |
-0.2
Source: PhysProp
|
| Predicted LogP |
-0.04
Calculated using ALOGPS
|
| Experimental LogS |
-2.87 [ADME Research, USCD] |
| Predicted LogS |
-2.94
Calculated using ALOGPS
|
| Experimental Caco2 Permeability |
Not Available |
| pKa/Isoelectric Point |
Not Available |
| Mass Spectrum |
Not Available
|
| MOL File |
Show | Download  |
| SDF File |
Show | Download  |
| PDB File |
Show | Download  |
| 2D Structure |
|
| 3D Structure |
|
| Experimental PDB ID |
1P87  |
| Experimental PDB File |
Show |
| Experimental PDB Structure |
|
| Isomeric SMILES |
C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)\C(C(=O)[C@@]3(O)C(=O)C2=C(O)C2=C1C=CC=C2O)=C(/N)O |
| Canonical SMILES |
CC1C2C(O)C3C(N(C)C)C(=O)C(C(=O)C3(O)C(=O)C2=C(O)C2=C1C=CC=C2O)=C(N)O |
| Drug Category |
- Anti-Bacterial Agents
- Antimalarials
- Tetracyclines
|
| ATC Codes |
|
| AHFS Codes |
|
| Indication |
For the treatment of infections caused by susceptible organisms. |
| Pharmacology |
Doxycycline, a long-acting tetracycline derived from oxytetracycline, is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with COPD, and adult periodontitis. |
| Mechanism of Action |
Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the 50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and inhibiting bacterial protein synthesis. |
| Absorption |
Completely absorbed following oral administration. |
| Toxicity |
Symptoms of overdose include anorexia, nausea, diarrhoea, glossitis, dysphagia, enterocolitis and inflammatory lesions (with monilial overgrowth) in the anogenital region, skin reactions such as maculopapular and erythematous rashes, exfoliative dermatitis, photosensitivity, hypersensitivity reactions such as urticaria, angioneurotic oedema, anaphylaxis, anaphyl-actoid purpura, pericarditis, and exacerbation of systemic lupus erythematosus, benign intracranial hypertension in adults disappearing on discontinuation of the medicine, haematologic abnormalities such as haemolytic anaemia, thrombocytopenia, neutropenia, and eosinophilia. LD50=262 mg/kg (I.P. in rat). |
| Protein Binding |
>90% |
| Biotransformation |
Hepatic |
| Half Life |
18-22 hours |
| Dosage Forms |
| Form |
Route |
| Capsule |
Oral |
| Gel, metered |
Periodontal |
| Tablet |
Oral |
|
| Patient Information |
Show  |
| Contraindications |
Show  |
| Interactions |
Show  |
| Drug Interactions |
| Drug |
Interaction |
| Acenocoumarol |
The tetracycline increases the anticoagulant effect |
| Acitretin |
Increased risk of intracranial hypertension |
| Aluminium |
Formation of non-absorbable complexes |
| Amobarbital |
The anticonvulsant decreases the effect of doxycycline |
| Amoxicillin |
Possible antagonism of action |
| Ampicillin |
Possible antagonism of action |
| Anisindione |
The tetracycline increases the anticoagulant effect |
| Aprobarbital |
The anticonvulsant decreases the effect of doxycycline |
| Attapulgite |
Formation of non-absorbable complexes |
| Azlocillin |
Possible antagonism of action |
| Aztreonam |
Possible antagonism of action |
| Bacampicillin |
Possible antagonism of action |
| Bismuth |
Formation of non-absorbable complexes |
| Butabarbital |
The anticonvulsant decreases the effect of doxycycline |
| Butalbital |
The anticonvulsant decreases the effect of doxycycline |
| Butethal |
The anticonvulsant decreases the effect of doxycycline |
| Calcium |
Formation of non-absorbable complexes |
| Carbamazepine |
The anticonvulsant decreases the effect of doxycycline |
| Carbenicillin |
Possible antagonism of action |
| Clavulanate |
Possible antagonism of action |
| Cloxacillin |
Possible antagonism of action |
| Cyclacillin |
Possible antagonism of action |
| Dicloxacillin |
Possible antagonism of action |
| Dicumarol |
The tetracycline increases the anticoagulant effect |
| Digoxin |
The tetracycline increases the effect of digoxin in 10% of patients |
| Dihydroquinidine barbiturate |
The anticonvulsant decreases the effect of doxycycline |
| Ethinyl Estradiol |
This anti-infectious agent could decrease the effect of the oral contraceptive |
| Ethotoin |
The anticonvulsant decreases the effect of doxycycline |
| Etretinate |
Increased risk of intracranial hypertension |
| Flucloxacillin |
Possible antagonism of action |
| Fosphenytoin |
The anticonvulsant decreases the effect of doxycycline |
| Heptabarbital |
The anticonvulsant decreases the effect of doxycycline |
| Hetacillin |
Possible antagonism of action |
| Hexobarbital |
The anticonvulsant decreases the effect of doxycycline |
| Insulin |
Tetracycline increases the risk of hypoglycemia |
| Insulin-aspart |
Tetracycline increases the risk of hypoglycemia |
| Insulin-detemir |
Tetracycline increases the risk of hypoglycemia |
| Insulin-glargine |
Tetracycline increases the risk of hypoglycemia |
| Insulin-glulisine |
Tetracycline increases the risk of hypoglycemia |
| Insulin-lispro |
Tetracycline increases the risk of hypoglycemia |
| Iron |
Formation of non-absorbable complexes |
| Isotretinoin |
Increased risk of intracranial hypertension |
| Magnesium |
Formation of non-absorbable complexes |
| Magnesium oxide |
Formation of non-absorbable complexes |
| Mephenytoin |
The anticonvulsant decreases the effect of doxycycline |
| Mestranol |
This anti-infectious agent could decrease the effect of the oral contraceptive |
| Methohexital |
The anticonvulsant decreases the effect of doxycycline |
| Methotrexate |
The tetracycline increases methotrexate toxicity |
| Methylphenobarbital |
The anticonvulsant decreases the effect of doxycycline |
| Meticillin |
Possible antagonism of action |
| Mezlocillin |
Possible antagonism of action |
| Nafcillin |
Possible antagonism of action |
| Oxacillin |
Possible antagonism of action |
| Penicillin G |
Possible antagonism of action |
| Penicillin V |
Possible antagonism of action |
| Pentobarbital |
The anticonvulsant decreases the effect of doxycycline |
| Phenobarbital |
The anticonvulsant decreases the effect of doxycycline |
| Phenytoin |
The anticonvulsant decreases the effect of doxycycline |
| Piperacillin |
Possible antagonism of action |
| Pivampicillin |
Possible antagonism of action |
| Pivmecillinam |
Possible antagonism of action |
| Primidone |
The anticonvulsant decreases the effect of doxycycline |
| Quinidine barbiturate |
The anticonvulsant decreases the effect of doxycycline |
| Rifabutin |
The rifamycin decreases the effect of doxycycline |
| Rifampin |
The rifamycin decreases the effect of doxycycline |
| Secobarbital |
The anticonvulsant decreases the effect of doxycycline |
| Talbutal |
The anticonvulsant decreases the effect of doxycycline |
| Tazobactam |
Possible antagonism of action |
| Ticarcillin |
Possible antagonism of action |
| Warfarin |
The tetracycline increases the anticoagulant effect |
| Zinc |
Formation of non-absorbable complexes |
|
| Food Interactions |
- Avoid alcohol.
- Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
- Take with a full glass of water Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
|
| Pathways |
| Name |
SMPDB Link |
KEGG Link |
| Doxycycline Pathway |
SMP00291  |
|
|
| General References |
- Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, Debrah AY, Pfarr KM, Adjei O, Buttner DW: Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol. 2003 Nov;192(4):211-6. Epub 2003 Mar 5. [PubMed
]
- Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A: Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet. 2005 Jun 18-24;365(9477):2116-21. [PubMed
]
- Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ: Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother. 2006 Sep;50(9):3124-31. [PubMed
]
- Drugs.com

- Wikipedia

- RxList

|
| Organisms Affected |
- Enteric bacteria and other eubacteria
|
| Phase 1 Metabolizing Enzymes |
- Cytochrome P450 3A43 (CYP3A43)
|
| Targets |
- 30S ribosomal protein S4
- 30S ribosomal protein S9
- 50S ribosomal protein L10
- 16S rRNA
|
|
Drug Target 1
[top]
|
| Target 1 ID |
22 |
| Target 1 Name |
30S ribosomal protein S4 |
| Target 1 Synonyms |
Not Available |
| Target 1 Gene Name |
rpsD |
| Target 1 Protein Sequence |
>30S ribosomal protein S4
ARYLGPKLKLSRREGTDLFLKSGVRAIDTKCKIEQAPGQHGARKPRLSDYGVQLREKQKV
RRIYGVLERQFRNYYKEAARLKGNTGENLLALLEGRLDNVVYRMGFGATRAEARQLVSHK
AIMVNGRVVNIASYQVSPNDVVSIREKAKKQSRVKAALELAEQREKPTWLEVDAGKMEGT
FKRKPERSDLSADINEHLIVELYSK
|
| Target 1 Number of Residues |
208 |
| Target 1 Molecular Weight |
23338 |
| Target 1 Theoretical pI |
10.66 |
| Target 1 GO Classification |
|
Function
|
binding
nucleic acid binding
RNA binding
structural molecule activity
structural constituent of ribosome |
|
Process
|
physiological process
metabolism
macromolecule metabolism
macromolecule biosynthesis
protein biosynthesis |
|
Component
|
cell
intracellular
protein complex
ribonucleoprotein complex
ribosome
small ribosomal subunit |
|
| Target 1 General Function |
Translation, ribosomal structure and biogenesis |
| Target 1 Specific Function |
Also functions as a rho-dependent antiterminator of rRNA transcription, increasing the synthesis of rRNA under conditions of excess protein, allowing a more rapid return to homeostasis. Binds directly to RNA polymerase |
| Target 1 Pathways |
Not Available
|
| Target 1 Reactions |
Not Available |
| Target 1 Pfam Domain Function |
|
| Target 1 Signals |
|
| Target 1 Transmembrane Regions |
|
| Target 1 Essentiality |
Essential |
| Target 1 GenBank ID Protein |
42798  |
| Target 1 UniProtKB/Swiss-Prot ID |
P0A7V8  |
| Target 1 UniProtKB/Swiss-Prot Entry Name |
RS4_ECOLI  |
| Target 1 PDB ID |
1P87  |
| Target 1 PDB File |
Show |
| Target 1 3D Structure |
|
| Target 1 Cellular Location |
|
| Target 1 Gene Sequence |
>621 bp
ATGGCAAGATATTTGGGTCCTAAGCTCAAGCTGAGCCGTCGTGAGGGCACCGACTTATTC
CTTAAGTCTGGCGTTCGCGCGATCGATACCAAGTGTAAAATTGAACAAGCTCCTGGCCAG
CACGGTGCGCGTAAACCGCGTCTGTCTGACTATGGTGTGCAGTTGCGTGAAAAGCAAAAA
GTTCGCCGTATCTATGGTGTGCTGGAGCGTCAGTTCCGTAACTACTACAAAGAAGCAGCA
CGTCTGAAAGGCAACACCGGTGAAAACCTGTTGGCTCTGCTGGAAGGTCGTCTGGACAAC
GTTGTATACCGTATGGGCTTCGGTGCCACTCGTGCAGAAGCACGTCAGCTGGTTAGCCAT
AAAGCAATTATGGTAAACGGTCGTGTTGTTAACATCGCTTCTTATCAGGTTAGTCCGAAT
GACGTTGTAAGCATTCGTGAGAAAGCGAAGAAGCAGTCTCGCGTGAAAGCCGCTCTGGAG
CTGGCTGAGCAGCGTGAAAAGCCAACCTGGCTGGAAGTTGATGCTGGCAAGATGGAAGGT
ACGTTTAAGCGTAAGCCGGAGCGTTCTGATCTGTCTGCGGACATTAACGAACACCTGATC
GTCGAGCTTTACTCCAAGTAA
|
| Target 1 GenBank Gene ID |
|
| Target 1 GeneCard ID |
Not Available |
| Target 1 GenAtlas ID |
Not Available |
| Target 1 HGNC ID |
Not Available |
| Target 1 Chromosome Location |
Not Available |
| Target 1 Locus |
Not Available |
| Target 1 SNPs |
SNPJam Report  |
| Target 1 General References |
- Arnold RJ, Reilly JP: Observation of Escherichia coli ribosomal proteins and their posttranslational modifications by mass spectrometry. Anal Biochem. 1999 Apr 10;269(1):105-12. [PubMed
]
- Schiltz E, Reinbolt J: Determination of the complete amino-acid sequence of protein S4 from Escherichia coli ribosomes. Eur J Biochem. 1975 Aug 15;56(2):467-81. [PubMed
]
- Dahlgren A, Ryden-Aulin M: A novel mutation in ribosomal protein S4 that affects the function of a mutated RF1. Biochimie. 2000 Aug;82(8):683-91. [PubMed
]
- Torres M, Condon C, Balada JM, Squires C, Squires CL: Ribosomal protein S4 is a transcription factor with properties remarkably similar to NusA, a protein involved in both non-ribosomal and ribosomal RNA antitermination. EMBO J. 2001 Jul 16;20(14):3811-20. [PubMed
]
- Tung CS, Joseph S, Sanbonmatsu KY: All-atom homology model of the Escherichia coli 30S ribosomal subunit. Nat Struct Biol. 2002 Oct;9(10):750-5. [PubMed
]
- Gao H, Sengupta J, Valle M, Korostelev A, Eswar N, Stagg SM, Van Roey P, Agrawal RK, Harvey SC, Sali A, Chapman MS, Frank J: Study of the structural dynamics of the E coli 70S ribosome using real-space refinement. Cell. 2003 Jun 13;113(6):789-801. [PubMed
]
- Nowotny V, Nierhaus KH: Assembly of the 30S subunit from Escherichia coli ribosomes occurs via two assembly domains which are initiated by S4 and S7. Biochemistry. 1988 Sep 6;27(18):7051-5. [PubMed
]
- Allen PN, Noller HF: Mutations in ribosomal proteins S4 and S12 influence the higher order structure of 16 S ribosomal RNA. J Mol Biol. 1989 Aug 5;208(3):457-68. [PubMed
]
- Bedwell D, Davis G, Gosink M, Post L, Nomura M, Kestler H, Zengel JM, Lindahl L: Nucleotide sequence of the alpha ribosomal protein operon of Escherichia coli. Nucleic Acids Res. 1985 Jun 11;13(11):3891-903. [PubMed
]
- Thomas MS, Bedwell DM, Nomura M: Regulation of alpha operon gene expression in Escherichia coli. A novel form of translational coupling. J Mol Biol. 1987 Jul 20;196(2):333-45. [PubMed
]
- 387752 Post LE, Nomura M: Nucleotide sequence of the intercistronic region preceding the gene for RNA polymerase subunit alpha in Escherichia coli. J Biol Chem. 1979 Nov 10;254(21):10604-6.
- 4587210 Reinbolt J, Schiltz E: The primary structure of ribosomal protein S4 from Escherichia coli. FEBS Lett. 1973 Nov 1;36(3):250-2.
- 7556101 Urlaub H, Kruft V, Bischof O, Muller EC, Wittmann-Liebold B: Protein-rRNA binding features and their structural and functional implications in ribosomes as determined by cross-linking studies. EMBO J. 1995 Sep 15;14(18):4578-88.
- 7559430 Baker AM, Draper DE: Messenger RNA recognition by fragments of ribosomal protein S4. J Biol Chem. 1995 Sep 29;270(39):22939-45.
- 9278503 Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
- 9716382 Choi KM, Atkins JF, Gesteland RF, Brimacombe R: Flexibility of the nascent polypeptide chain within the ribosome--contacts from the peptide N-terminus to a specific region of the 30S subunit. Eur J Biochem. 1998 Jul 15;255(2):409-13.
|
| Target 1 Drug References |
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed
]
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed
]
|
|
Drug Target 2
[top]
|
| Target 2 ID |
140 |
| Target 2 Name |
30S ribosomal protein S9 |
| Target 2 Synonyms |
Not Available |
| Target 2 Gene Name |
rpsI |
| Target 2 Protein Sequence |
>30S ribosomal protein S9
AENQYYGTGRRKSSAARVFIKPGNGKIVINQRSLEQYFGRETARMVVRQPLELVDMVEKL
DLYITVKGGGISGQAGAIRHGITRALMEYDESLRSELRKAGFVTRDARQVERKKVGLRKA
RRRPQFSKR
|
| Target 2 Number of Residues |
131 |
| Target 2 Molecular Weight |
14725 |
| Target 2 Theoretical pI |
11.52 |
| Target 2 GO Classification |
|
Function
|
structural molecule activity
structural constituent of ribosome |
|
Process
|
physiological process
metabolism
macromolecule metabolism
macromolecule biosynthesis
protein biosynthesis |
|
Component
|
protein complex
ribonucleoprotein complex
ribosome
cell
intracellular |
|
| Target 2 General Function |
Translation, ribosomal structure and biogenesis |
| Target 2 Specific Function |
The C-terminal tail plays a role in the affinity of the 30S P site for different tRNAs. Mutations that decrease this affinity are suppressed in the 70S ribosome |
| Target 2 Pathways |
Not Available
|
| Target 2 Reactions |
Not Available |
| Target 2 Pfam Domain Function |
|
| Target 2 Signals |
|
| Target 2 Transmembrane Regions |
|
| Target 2 Essentiality |
Essential |
| Target 2 GenBank ID Protein |
535073  |
| Target 2 UniProtKB/Swiss-Prot ID |
P0A7X3  |
| Target 2 UniProtKB/Swiss-Prot Entry Name |
RS9_ECOLI  |
| Target 2 PDB ID |
1P87  |
| Target 2 PDB File |
Show |
| Target 2 3D Structure |
|
| Target 2 Cellular Location |
Not Available |
| Target 2 Gene Sequence |
>393 bp
ATGGCTGAAAATCAATACTACGGCACTGGTCGCCGCAAAAGTTCCGCAGCTCGCGTTTTC
ATCAAACCGGGCAACGGTAAAATCGTAATCAACCAACGTTCTCTGGAACAGTACTTCGGT
CGTGAAACTGCCCGCATGGTAGTTCGTCAGCCGCTGGAACTGGTCGACATGGTTGAGAAA
CTGGACCTGTACATCACCGTTAAAGGTGGTGGTATCTCTGGTCAGGCTGGTGCGATCCGT
CACGGTATCACCCGCGCTCTGATGGAATACGACGAGTCCCTGCGTTCTGAACTGCGTAAA
GCTGGCTTCGTTACTCGTGACGCTCGTCAGGTTGAACGTAAGAAAGTCGGTCTGCGTAAA
GCACGTCGTCGTCCGCAGTTCTCCAAACGTTAA
|
| Target 2 GenBank Gene ID |
|
| Target 2 GeneCard ID |
Not Available |
| Target 2 GenAtlas ID |
Not Available |
| Target 2 HGNC ID |
Not Available |
| Target 2 Chromosome Location |
Not Available |
| Target 2 Locus |
Not Available |
| Target 2 SNPs |
SNPJam Report  |
| Target 2 General References |
- Arnold RJ, Reilly JP: Observation of Escherichia coli ribosomal proteins and their posttranslational modifications by mass spectrometry. Anal Biochem. 1999 Apr 10;269(1):105-12. [PubMed
]
- Chen R, Wittmann-Liebold B: The primary structure of protein S9 from the 30S subunit of Escherichia coli ribosomes. FEBS Lett. 1975 Mar 15;52(1):139-40. [PubMed
]
- Tung CS, Joseph S, Sanbonmatsu KY: All-atom homology model of the Escherichia coli 30S ribosomal subunit. Nat Struct Biol. 2002 Oct;9(10):750-5. [PubMed
]
- Gao H, Sengupta J, Valle M, Korostelev A, Eswar N, Stagg SM, Van Roey P, Agrawal RK, Harvey SC, Sali A, Chapman MS, Frank J: Study of the structural dynamics of the E coli 70S ribosome using real-space refinement. Cell. 2003 Jun 13;113(6):789-801. [PubMed
]
- Isono S, Thamm S, Kitakawa M, Isono K: Cloning and nucleotide sequencing of the genes for ribosomal proteins S9 (rpsI) and L13 (rplM) of Escherichia coli. Mol Gen Genet. 1985;198(2):279-82. [PubMed
]
- Marsh RC, Parmeggiani A: Requirement of proteins S5 and S9 from 30S subunits for the ribosome-dependent GTPase activity of elongation factor G. Proc Natl Acad Sci U S A. 1973 Jan;70(1):151-5. [PubMed
]
- Urlaub H, Kruft V, Bischof O, Muller EC, Wittmann-Liebold B: Protein-rRNA binding features and their structural and functional implications in ribosomes as determined by cross-linking studies. EMBO J. 1995 Sep 15;14(18):4578-88. [PubMed
]
- Osswald M, Doring T, Brimacombe R: The ribosomal neighbourhood of the central fold of tRNA: cross-links from position 47 of tRNA located at the A, P or E site. Nucleic Acids Res. 1995 Nov 25;23(22):4635-41. [PubMed
]
- Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74. [PubMed
]
|
| Target 2 Drug References |
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed
]
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed
]
|
|
Drug Target 3
[top]
|
| Target 3 ID |
818 |
| Target 3 Name |
50S ribosomal protein L10 |
| Target 3 Synonyms |
Not Available |
| Target 3 Gene Name |
rplJ |
| Target 3 Protein Sequence |
>50S ribosomal protein L10
ALNLQDKQAIVAEVSEVAKGALSAVVADSRGVTVDKMTELRKAGREAGVYMRVVRNTLLR
RAVEGTPFECLKDAFVGPTLIAYSMEHPGAAARLFKEFAKANAKFEVKAAAFEGELIPAS
QIDRLATLPTYEEAIARLMATMKEASAGKLVRTLAAVRDAKEAA
|
| Target 3 Number of Residues |
166 |
| Target 3 Molecular Weight |
17581 |
| Target 3 Theoretical pI |
9.51 |
| Target 3 GO Classification |
|
Function
|
structural molecule activity
structural constituent of ribosome |
|
Process
|
metabolism
macromolecule metabolism
macromolecule biosynthesis
protein biosynthesis
physiological process
cellular physiological process
cell organization and biogenesis
organelle organization and biogenesis
ribosome biogenesis and assembly |
|
Component
|
protein complex
ribonucleoprotein complex
ribosome
cell
intracellular |
|
| Target 3 General Function |
Translation, ribosomal structure and biogenesis |
| Target 3 Specific Function |
Protein L10 is also a translational repressor protein. It controls the translation of the rplJL-rpoBC operon by binding to its mRNA |
| Target 3 Pathways |
Not Available
|
| Target 3 Reactions |
Not Available |
| Target 3 Pfam Domain Function |
|
| Target 3 Signals |
|
| Target 3 Transmembrane Regions |
|
| Target 3 Essentiality |
Essential |
| Target 3 GenBank ID Protein |
24054563  |
| Target 3 UniProtKB/Swiss-Prot ID |
P0A7J6  |
| Target 3 UniProtKB/Swiss-Prot Entry Name |
RL10_SHIFL  |
| Target 3 PDB ID |
Not Available |
| Target 3 Cellular Location |
Not Available |
| Target 3 Gene Sequence |
>498 bp
ATGGCTTTAAATCTTCAAGACAAACAAGCGATTGTTGCTGAAGTCAGCGAAGTAGCCAAA
GGCGCGCTGTCTGCAGTAGTTGCGGATTCCCGTGGCGTAACTGTAGATAAAATGACTGAA
CTGCGTAAAGCAGGTCGCGAAGCTGGCGTATACATGCGTGTTGTTCGTAACACCCTGCTG
CGCCGTGCTGTTGAAGGTACTCCGTTCGAGTGCCTGAAAGACGCGTTTGTTGGTCCGACC
CTGATTGCATACTCTATGGAACACCCGGGCGCTGCTGCTCGTCTGTTCAAAGAGTTCGCG
AAAGCGAATGCAAAATTTGAGGTCAAAGCCGCTGCCTTTGAAGGTGAGCTGATCCCGGCG
TCTCAGATCGACCGCCTGGCAACTCTGCCGACCTACGAAGAAGCAATTGCACGCCTGATG
GCAACCATGAAAGAAGCTTCGGCTGGCAAACTGGTTCGTACTCTGGCTGCTGTACGCGAT
GCGAAAGAAGCTGCTTAA
|
| Target 3 GenBank Gene ID |
|
| Target 3 GeneCard ID |
Not Available |
| Target 3 GenAtlas ID |
Not Available |
| Target 3 HGNC ID |
Not Available |
| Target 3 Chromosome Location |
Not Available |
| Target 3 Locus |
Not Available |
| Target 3 SNPs |
SNPJam Report  |
| Target 3 General References |
- Jin Q, Yuan Z, Xu J, Wang Y, Shen Y, Lu W, Wang J, Liu H, Yang J, Yang F, Zhang X, Zhang J, Yang G, Wu H, Qu D, Dong J, Sun L, Xue Y, Zhao A, Gao Y, Zhu J, Kan B, Ding K, Chen S, Cheng H, Yao Z, He B, Chen R, Ma D, Qiang B, Wen Y, Hou Y, Yu J: Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res. 2002 Oct 15;30(20):4432-41. [PubMed
]
- Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G 3rd, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR: Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun. 2003 May;71(5):2775-86. [PubMed
]
|
| Target 3 Drug References |
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed
]
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed
]
|
|
Drug Target 4
[top]
|
| Target 4 ID |
883 |
| Target 4 Name |
16S rRNA |
| Target 4 Synonyms |
- 16S ribosomal ribonucleic acid
|
| Target 4 Gene Name |
Not Available |
| Target 4 Protein Sequence |
Not Available |
| Target 4 Number of Residues |
0 |
| Target 4 Molecular Weight |
Not Available |
| Target 4 Theoretical pI |
Not Available |
| Target 4 GO Classification |
|
Function
|
transferase activity
translation
RNA binding
|
|
Process
|
rRNA processing
RNA processing and modification
|
|
Component
|
| cell |
|
| Target 4 General Function |
Translation, ribosomal structure and biogenesis |
| Target 4 Specific Function |
In prokaryotes, the 16S rRNA is essential for recognizing the 5' end of mRNA and hence positioning it correctly on the ribosome. The 16S rRNA has a characteristic secondary structure in which half of the nucleotides are base-paired. The 16S rRNA sequence has been highly conserved and is often used for evolutionary and species comparative analysis. |
| Target 4 Pathways |
| Name |
SMPDB Link |
KEGG Link |
| Ribosome |
|
map03010  |
|
| Target 4 Reactions |
- rRNA + mRNA + Amino Acids = Polypeptide
|
| Target 4 Pfam Domain Function |
Not Available |
| Target 4 Signals |
|
| Target 4 Transmembrane Regions |
|
| Target 4 Essentiality |
Essential |
| Target 4 GenBank ID Protein |
Not Available |
| Target 4 UniProtKB/Swiss-Prot ID |
Not Available |
| Target 4 UniProtKB/Swiss-Prot Entry Name |
Not Available |
| Target 4 PDB ID |
1EMI  |
| Target 4 PDB File |
Show |
| Target 4 3D Structure |
|
| Target 4 Cellular Location |
|
| Target 4 Gene Sequence |
>16S rRNA sequence
AAATTGAAGAGTTTGATCATGGCTCAGATTGAACGCTGGCGGCAGGCCTAACACATGCAA
GTCGAACGGTAACAGGAAACAGCTTGCTGTTTCGCTGACGAGTGGCGGACGGGTGAGTAA
TGTCTGGGAAACTGCCTGATGGAGGGGGATAACTACTGGAAACGGTAGCTAATACCGCAT
AACGTCGCAAGACCAAAGAGGGGGACCCTCGGGCCTCTTGCCATCGGATGTGCCCAGATG
GGATTAGCTTGTTGGTGGGGTAACGGCTCACCAAGGCGACGATCCCTAGCTGGTCTGAGA
GGATGACCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGG
GGAATATTGCACAATGGGCGCAAGCCTGATGCAGCCATGCCGCGTGTATGAAGAAGGCCT
TCGGGTTGTAAAGTACTTTCAGCGGGGAGGAAGGGAGTAAAGTTAATACCTTTGCTCATT
GACGTTACCCGCAGAAGAAGCACCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAG
GGTGCAAGCGTTAATCGGAATTACTGGGCGTAAAGCGCACGCAGGCGGTTTGTTAAGTCA
GATGTGAAATCCCCGGGCTCAACCTGGGAACTGCATCTGATACTGGCAAGCTTGAGTCTC
GTAGAGGGGGGTAGAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACC
GGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCA
AACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGTCGACTTGGAGGTTGTGCC
CTTGAGGCGTGGCTTCCGGAGCTAACGCGTTAAGTCGACCGCCTGGGGAGTACGGCCGCA
AGGTTAAAACTCAAATGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAAT
TCGATGCAACGCGAAGAACCTTACCTGGTCTTGACATCCACGGAAGTTTTCAGAGATGAG
AATGTGCCTTCGGGAACCGTGAGACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTTGTGA
AATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATCCTTTGTTGCCAGCGGTCCGGC
CGGGAACTCAAAGGAGACTGCCAGTGATAAACTGGAGGAAGGTGGGGATGACGTCAAGTC
ATCATGGCCCTTACGACCAGGGCTACACACGTGCTACAATGGCGCATACAAAGAGAAGCG
ACCTCGCGAGAGCAAGCGGACCTCATAAAGTGCGTCGTAGTCCGGATTGGAGTCTGCAAC
TCGACTCCATGAAGTCGGAATCGCTAGTAATCGTGGATCAGAATGCCACGGTGAATACGT
TCCCGGGCCTTGTACACACCGCCCGTCACACCATGGGAGTGGGTTGCAAAAGAAGTAGGT
AGCTTAACCTTCGGGAGGGCGCTTACCACTTTGTGATTCATGACTGGGGTGAAGTCGTAA
CAAGGTAACCGTAGGGGAACCTGCGGTTGGATCACCTCCTTA
|
| Target 4 GenBank Gene ID |
|
| Target 4 GeneCard ID |
Not Available |
| Target 4 GenAtlas ID |
Not Available |
| Target 4 HGNC ID |
Not Available |
| Target 4 Chromosome Location |
Not Available |
| Target 4 Locus |
Not Available |
| Target 4 SNPs |
Not Available |
| Target 4 General References |
- Gu XR, Gustafsson C, Ku J, Yu M, Santi DV: Identification of the 16S rRNA m5C967 methyltransferase from Escherichia coli. Biochemistry. 1999 Mar 30;38(13):4053-7. [PubMed
]
- Martin JF, Barreiro C, Gonzalez-Lavado E, Barriuso M: Ribosomal RNA and ribosomal proteins in corynebacteria. J Biotechnol. 2003 Sep 4;104(1-3):41-53. [PubMed
]
- Srivastava AK, Schlessinger D: Structure and organization of ribosomal DNA. Biochimie. 1991 Jun;73(6):631-8. [PubMed
]
- Gutell RR, Larsen N, Woese CR: Lessons from an evolving rRNA: 16S and 23S rRNA structures from a comparative perspective. Microbiol Rev. 1994 Mar;58(1):10-26. [PubMed
]
|
| Target 4 Drug References |
- Eremeeva ME, Bosserman EA, Demma LJ, Zambrano ML, Blau DM, Dasch GA: Isolation and identification of Rickettsia massiliae from Rhipicephalus sanguineus ticks collected in Arizona. Appl Environ Microbiol. 2006 Aug;72(8):5569-77. [PubMed
]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed
]
- Kumar S, Kutlin A, Roblin P, Kohlhoff S, Bodetti T, Timms P, Hammerschlag MR: Isolation and antimicrobial susceptibilities of Chlamydial isolates from Western barred bandicoots. J Clin Microbiol. 2007 Feb;45(2):392-4. Epub 2006 Nov 22. [PubMed
]
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed
]
- Pringle M, Fellstrom C, Johansson KE: Decreased susceptibility to doxycycline associated with a 16S rRNA gene mutation in Brachyspira hyodysenteriae. Vet Microbiol. 2007 Jul 20;123(1-3):245-8. Epub 2007 Feb 25. [PubMed
]
|